Fresenius Kabi’s mAbxience S.L. is set to play its part in a “historic milestone in the production of biopharmaceuticals in Turkey,” after announcing what was termed a “significant” technology transfer agreement with local player Abdi Ibrahim Pharmaceuticals, “specifically focusing on a crucial cancer drug.”
The transfer is set to enable the production of a ‘bio-product’ used in treating metastatic colorectal cancer, cervical cancer, and...






